Sotera Health Company SHC
- Market cap
- $5.3B
- P/E
- 32.1×
Follow SHC
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | 24.05 | 20.48 | 5.78 | 8.02 | 10.71 | 9.53 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | 29.00 | 30.38 | 24.90 | 19.40 | 17.44 | 17.83 |
High Price
|
|||
| — | — | — | 2,900 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 |
Employees
|
|||
| — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | 746 | 778 | 818 | 931 | 1,004 | 1,049 | 1,100 | 1,164 |
Revenue
|
|||
| — | — | 47.88% | 50.81% | 54.22% | 55.68% | 55.50% | 55.00% | 54.73% | 55.48% |
Gross Margin
|
|||
| — | — | 24 | (1) | (39) | 176 | (243) | 106 | 114 | 148 |
EBT
|
|||
| — | — | 3.25% | (0.12%) | (4.75%) | 18.86% | (24.22%) | 10.10% | 10.35% | 12.68% |
EBT Margin
|
|||
| — | 0 | (6) | (20) | (37) | 117 | (234) | 51 | 44 | 78 |
Net Income
|
|||
| — | — | 204 | 155 | 155 | 157 | 161 | 167 | 171 | 142 |
Depreciation
|
|||
| — | — | 3.21 | 3.35 | 3.44 | 3.34 | 3.58 | 3.73 | 3.89 | 4.10 |
Revenue/Sh
|
|||
| — | — | (0.03) | (0.09) | (0.16) | 0.41 | (0.83) | 0.18 | 0.16 | 0.27 |
Earnings/Sh
|
|||
| — | — | 0.51 | 0.64 | 0.51 | 1.01 | 0.99 | (0.53) | 0.79 | 1.01 |
Cash Flow/Sh
|
|||
| — | — | (0.31) | (0.25) | (0.23) | (0.37) | (0.65) | (0.76) | (0.63) | (0.49) |
Capex/Sh
|
|||
| — | — | 0.20 | 0.39 | 0.28 | 0.64 | 0.34 | (1.29) | 0.16 | 0.53 |
Free CF/Sh
|
|||
| — | — | 0.20 | (2.76) | 1.91 | 2.10 | 1.25 | 1.58 | 1.43 | 2.13 |
Book Value/Sh
|
|||
| — | — | 232 | 232 | 238 | 279 | 280 | 281 | 283 | 284 |
Shares
|
|||
| — | — | 4,648.15 | 4,648.15 | 0.00 | 56.07 | 0.00 | 93.06 | 91.20 | 65.33 |
PE Ratio
|
|||
| — | — | 7.32 | 7.32 | 8.50 | 7.06 | 2.32 | 4.49 | 3.52 | 4.30 |
PS Ratio
|
|||
| — | — | 0.00 | 0.00 | 15.30 | 11.22 | 6.66 | 10.61 | 9.55 | 8.27 |
PB Ratio
|
|||
| — | — | 10.94 | 10.94 | 10.66 | 8.87 | 3.92 | 6.34 | 5.37 | 5.93 |
EV/Sales
|
|||
| — | — | 55.56 | 55.56 | 130.05 | 46.07 | 41.20 | (18.34) | 131.01 | 46.23 |
EV/FCF
|
|||
| — | — | 120 | 149 | 121 | 282 | 278 | (148) | 224 | 287 |
Op' Cash Flow
|
|||
| — | — | (73) | (57) | (54) | (102) | (182) | (215) | (179) | (138) |
Capex
|
|||
| — | — | 47 | 92 | 67 | 179 | 96 | (363) | 45 | 149 |
FCF
|
|||
| — | — | 169 | 128 | 174 | 185 | (147) | 327 | 335 | 364 |
Working Cap'
|
|||
| — | — | 2,236 | 2,847 | 1,871 | 1,794 | 2,001 | 2,249 | 2,318 | 2,235 |
Total Debt
|
|||
| — | — | 2,140 | 2,784 | 1,768 | 1,687 | 1,605 | 1,947 | 2,039 | 1,888 |
Net Debt
|
|||
| — | — | 45 | (641) | 455 | 586 | 350 | 444 | 405 | 606 |
Sh' Equity
|
|||
| — | — | (0.43%) | (0.79%) | (1.45%) | 4.21% | (7.91%) | 1.64% | 1.43% | 2.46% |
ROA
|
|||
| — | — | 2.31% | 5.35% | 5.79% | 7.06% | 7.94% | 7.23% | 7.61% | 9.07% |
ROIC
|
|||
| — | — | 1.96% | 7.00% | 41.40% | 22.46% | (49.89%) | 12.87% | 10.45% | 15.42% |
ROE
|
|||
Sotera Health Company peers in Diagnostics & Research
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| GRAL GRAIL, Inc. | $5.5B | 0.0× | Compare |
| RDNT RadNet, Inc. | $5.6B | 0.0× | Compare |
| BLLN BillionToOne, Inc. | $5.9B | 119× | Compare |
| ADPT Adaptive Biotechnologies Corporation | $4.7B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| VCYT Veracyte, Inc. | $3.9B | 31.5× | Compare |
| CDNA CareDx, Inc. | $3.2B | 29.6× | Compare |
| QGEN QIAGEN N.V. | $9.3B | 22.6× | Compare |
| WGS GeneDx Holdings Corp. | $2.6B | 0.0× | Compare |
Sotera Health Company (SHC) key facts
- Sotera Health Company (SHC) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
- Sotera Health Company’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 5.74% from fiscal 2024.
- Net income was $77.9 million, or $0.27 per share (basic), a net margin of 6.70%.
- As of September 25, 2026, SHC traded at $18.34, a market capitalization of $5.3 billion.
- At that price the stock trades at 32.1× trailing-twelve-month earnings and 4.3× sales.
- Return on equity was 15.4% and debt-to-equity 3.35.
Sotera Health Company (SHC) Latest News
15 Sep
Sotera Health Company (SHC) stock surges 25% in Q2. 25% stock surge signals major positive shift in valuation and investor sentiment.
16 Aug
Sotera Health Company released Q2 earnings, triggering buy, sell or hold stock analysis based on financial results and outlook. Q2 earnings data can shift near-term investor views and trading in SHC shares.
15 Aug
Sotera Health Company held its Q2 earnings call and addressed the top 5 analyst questions on company performance and outlook. Q2 earnings call and analyst questions offer moderate insights into financials and sentiment without major new strategic shifts.
13 Aug
Sotera Health (SHC) presented Q2 2026 financial results, operational updates and outlook during its earnings call. Quarterly earnings and guidance directly shape near-term financial views and stock reaction.
10 Aug
Sotera Health Company reported positive results while securing wins in litigations. Litigation wins paired with positive results reduce legal risks and strengthen financial outlook.
9 Aug
Sotera Health reported broad-based Q2 growth, executed a leadership transition, and advanced strategic investments that shape its outlook. Broad-based growth, leadership transition, and strategic investments point to major shifts likely to alter SHC trajectory and investor views.
7 Aug
Sotera Health shares rose 5.9% after the company beat Q2 earnings expectations and raised full-year guidance. Q2 earnings beat plus raised guidance improves near-term financial outlook and supports stock gains.
Sotera Health Q2 earnings call highlighted financial results, operational updates, and forward guidance for the company. Quarterly earnings details typically drive moderate short-term shifts in investor sentiment and valuation without transforming long-term strategy.
6 Aug
Sotera Health achieved strong second-quarter and first-half 2026 results and raised its full-year 2026 outlook. Strong results and raised guidance signal enhanced future performance prospects.
Sotera Health Company reported Q2 2026 results and discussed operations, financials, and outlook during its earnings call. Quarterly earnings call delivers financial metrics and guidance that shape near-term investor sentiment and valuation.
Sotera Health Company reported stronger than expected Q2 CY2026 financial results. Strong quarterly earnings beat can lift near-term stock price and sentiment but rarely shifts long-term company trajectory.
26 May
Sotera Health refinanced its term loan at a lower interest margin, potentially altering the bullish investment outlook for the stock. Refinancing lowers interest costs and directly affects financial performance and investor views on future prospects.
25 May
Sotera Health (SHC) delivered strong Q1 results that beat expectations and raised its full-year outlook. Q1 earnings beat combined with raised full-year guidance signals stronger financial performance and improved investor sentiment.
22 May
Sotera Health Company reported Q1 earnings results, benchmarked against peers in the research tools and consumables sector. Q1 earnings data can moderately shift near-term investor views on SHC financial performance and sector positioning.
15 May
Sotera Health Company’s Q1 earnings call featured five revealing analyst questions probing key issues in operations, growth prospects, and market challenges. Analyst questions highlight moderately influential topics on financial performance and strategic outlook for Sotera Health.
13 May
Sotera Health (NASDAQ:SHC) reported solid earnings reinforced by other strong factors. Solid earnings backed by strong factors indicate significant positive influence on SHC's financial performance and investor sentiment.
5 May
Sotera Health Company released Q1 2026 earnings call summary detailing financial performance, operational updates, and future outlook. Q1 earnings call summary reveals financial results and guidance significantly shaping investor expectations and stock trajectory.
Sotera Health (SHC) Q1 earnings report details key metrics performance compared to Wall Street estimates, highlighting revenue, EPS, and operational results against analyst forecasts. Q1 earnings metrics versus Wall Street estimates directly drive stock volatility and investor confidence in SHC's trajectory.
Sotera Health Company (SHC) surpassed Q1 earnings and revenue estimates, demonstrating strong financial performance. Surpassing Q1 earnings and revenue estimates boosts investor sentiment and signals robust financial health.
Sotera Health Company (NASDAQ:SHC) beat revenue expectations in Q1 CY2026, driving its stock to soar. Revenue beat in Q1 CY2026 triggered stock surge, positively impacting financial performance and investor sentiment.
Sotera Health Company delivered strong first-quarter 2026 results and reaffirmed its full-year 2026 outlook. Strong Q1 results and reaffirmed outlook positively influence financial performance and investor sentiment significantly.
Sotera Health Company (SHC) released Q1 earnings call highlights covering financial results, operational updates, and future outlook. Q1 earnings call highlights impact financial performance and market sentiment but are balanced by quarterly nature.
Sotera Health Company announces leadership transition. Leadership transitions often moderately impact strategic direction and market sentiment without fundamentally altering long-term prospects.
22 Apr
Sotera Health (SHC) released Q3 2024 earnings call transcript detailing financial results, operational updates, and management outlook. Q3 2024 earnings transcript discloses financial performance and guidance directly impacting SHC's trajectory and investor sentiment.
8 Apr
Sotera Health Company (SHC) stock faces Buy, Sell, or Hold debate following Q4 earnings release, evaluating financial results, guidance, and market outlook. Q4 earnings directly impact SHC's financial trajectory, guidance, and investor sentiment.
OKLO advances its isotope production initiatives, potentially enabling long-term growth opportunities for Sotera Health Company (SHC) through enhanced supply for sterilization services. OKLO's isotope push offers moderate potential to bolster SHC's supply chain and growth in medical sterilization.
27 Mar
Sotera Health Company (NASDAQ:SHC) Q4 performance is reviewed and compared to other Research Tools & Consumables stocks. Q4 rundown versus sector peers affects competitive positioning and investor sentiment on financial performance.
23 Mar
A $175 million investment into Sotera Health Company signals potential opportunity amid a 21% stock drop. $175 million investment amid 21% stock drop demonstrates major investor confidence likely to significantly improve SHC's trajectory and sentiment.
22 Mar
Sotera Health CFO affirms growth story intact and projects 5%-6.5% organic growth for 2026 at KeyBanc Forum. CFO's forward guidance on intact growth and 5%-6.5% organic expansion in 2026 significantly boosts long-term outlook and investor confidence.
15 Mar
Sotera Health Company (SHC) stock plunged 72% in a year, yet an investor bought $12 million worth amid the decline. Investor purchase of $12 million despite 72% stock drop signals confidence and may moderately boost market sentiment.